CMRX / Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out i more_horizontal

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of S more_horizontal

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, more_horizontal

The biotechnology firm Chimerix has a high probability of success in its ongoing clinical trial in the treatment of pediatric brain tumors, according more_horizontal

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strat more_horizontal

Chimerix, Inc. (NASDAQ:CMRX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strat more_horizontal

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Chimerix, Inc. (NASDAQ:CMRX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-St more_horizontal